In a phase I trial on resectable HER2+ breast cancer (Knutson et al., 2019), kinds of research developed a degenerate HER2 epitope-based vaccine consisting of four HLA class II-restricted epitopes mixed with granulocyte-macrophage colony stimulating factor. This evidence concerns the gene ERBB2 and breast carcinoma.